ReviewDermatology and therapy2026
Beyond the Skin: Assessing Itch in Atopic Dermatitis - Insights from UK Dermatologists. A Cross-Sectional Survey and Narrative Review.
Review in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic itch is the most burdensome symptom of atopic dermatitis (AD), yet its routine assessment and measurement remain inconsistent.
objectivesThis study aimed to characterise current practices for evaluating itch in AD among UK dermatologists and, through a narrative review, to summarise available itch assessment tools and inform practical recommendations for routine practice.
designThis was a cross-sectional clinician survey and narrative literature review. A total of 394 dermatologists participated in the survey of itch and its assessment in AD during the 2024 British Association of Dermatologists Annual Meeting.
resultsDermatologists reported itch as the most bothersome symptom in atopic dermatitis (78.68%, n = 310), and nearly half identified itch as the strongest predictor of disease severity (47.97%, n = 189). Only 28.68% of respondents (n = 113) reported assessing itch often or always using the peak pruritus numerical scale (PP-NRS) or visual analogue scale (VAS), while 45.18% (n = 178) assessed itch sometimes and 26.14% (n = 103) never assessed itch. Reduction of itch was selected as the most important treatment goal by 56.35% of respondents (n = 222). In addition, 94.16% (n = 371) agreed or strongly agreed that they routinely try to understand the impact of itch on their patients, and 74.11% (n = 292) agreed or strongly agreed that there is currently a lack of effective treatment options for itch relief. The narrative review identified validated unidimensional itch measures (numerical rating scale (NRS), VAS, verbal rating scale (VRS)) and multidimensional instruments (Patient-Oriented Scoring of Atopic Dermatitis (PO-SCORAD), Patient-Oriented Eczema Measure (POEM), 5-D itch scale, ItchyQOL), with clinical studies reporting that reductions of approximately 3-4 points on the itch NRS correspond to patient-perceived meaningful improvement.
conclusionThis large UK-based survey among dermatologists highlighted a gap between recognition of itch burden in atopic dermatitis and its systematic measurement in routine practice. The accompanying narrative review identified simple patient-reported measures, including the numerical rating scale (NRS), as feasible options to support more consistent itch assessment in routine care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.